KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Liabilities: 2011-2024

Historic Total Liabilities for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $332.3 million.

  • Supernus Pharmaceuticals' Total Liabilities rose 10.29% to $370.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $370.1 million, marking a year-over-year increase of 10.29%. This contributed to the annual value of $332.3 million for FY2024, which is 6.69% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Total Liabilities stood at $332.3 million for FY2024, which was down 6.69% from $356.2 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Total Liabilities registered a high of $873.3 million during FY2021, and its lowest value of $332.3 million during FY2024.
  • In the last 3 years, Supernus Pharmaceuticals' Total Liabilities had a median value of $356.2 million in 2023 and averaged $501.6 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Total Liabilities skyrocketed by 34.41% in 2020 and then tumbled by 56.37% in 2023.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Total Liabilities stood at $759.2 million in 2020, then increased by 15.02% to $873.3 million in 2021, then decreased by 6.53% to $816.3 million in 2022, then plummeted by 56.37% to $356.2 million in 2023, then decreased by 6.69% to $332.3 million in 2024.